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Preface to Mitochondria and CardioprotectionDue to the abundance of mitochondria in cardiac myocytes and
to the strict dependence of myocardial function on oxidative
phosphorylation, it is hardly surprising that studies focusing on
these organelles have been always pivotal in cardiovascular
research. This holds especially true for research related to
myocardial ischemia/reperfusion (I/R) and cardioprotective in-
terventions starting during the 1960s, soon after it became clear
that mitochondria are the site of oxidative metabolism and energy
conservation. Our current understanding of I/R injury is greatly
contributed by the notion that mitochondria are both a central
target of processes triggered by ischemia and a pivotal site for
determining the loss of cell viability. Therefore, strategies aimed at
protecting against I/R injury have focused on mitochondria. The
advances in this ﬁeld of research represent a striking example of
translational medicine. However, many mechanistic details are far
from being elucidated, and numerous novel aspects have recently
been added by genetics, protein analyses and cell biology showing
the endless appeal of mitochondrial studies in the cardiovascular
ﬁeld.
This issue is aimed at reviewing the processes triggered by I/R that
alter mitochondria, the signaling pathways that maintain mitochon-
drial function counteracting myocardial I/R injury, and the pharma-
cological approaches that act at the mitochondrial level to protect
against derangements induced by I/R.
The articles move from mechanisms involved in mitochondrial
metabolism to aspects related to injury and protection of ischemic
hearts, ﬁnally extending to the involvement of mitochondrial
dysfunction in myocardial failure. In particular, the ﬁrst two
reviews (by G. L. Semenza and R.L. Scarpulla, respectively) analyze
how oxygen availability and oxidative metabolism modulate
mitochondrial biogenesis by means of PGC1-α and HIF1α, respec-
tively. Besides mechanisms controlling protein expression, func-
tional changes associated with oxidative metabolism and
mitochondrial function can result from post-translational modiﬁca-
tions of proteins. In this respect M.N. Sack reviews the emerging
role of (de)acetylation associated with nutrient availability through
sirtuin action. Another modality to change mitochondrial protein
composition is by means of translocation of cytosolic components
into mitochondrial compartments. This aspect is reviewed by K.
Boengler et al. especially discussing the role of mitochondrial
protein import in cardioprotection. On the other hand, as reviewed
by R. Gottlieb the susceptibility to injury is likely to be heavily
inﬂuenced by the autophagic control of protein and organelle
quality. The central set of reviews is focused on cardioprotection
highlighting the role of reactive oxygen and nitrogen species. In
reviewing signal pathways mediating mitochondrial and myocardial
protection E. Murphy and C. Steenbergen point out the role of S-
nitrosylation of mitochondrial proteins. This aspect is addressed
also by P. Brookes et al. who highlight the role of S-nitrosylation in0167-4889/$ – see front matter © 2011 Published by Elsevier B.V.
doi:10.1016/j.bbamcr.2011.05.011redox modulation of the mitochondrial KATP channel. The opening
of this channel and/or a decreased open probability of another large
conductance channel, the mitochondrial permeability transition
pore (PTP), are considered crucial for counteracting I/R injury.
Despite the uncertainty in the molecular identity of these channels,
a general consensus exists that the inhibition of PTP opening
protects against I/R injury, a concept that has been supported by
both experimental ﬁndings obtained in various organs and clinical
evidence. However, as detailed in Bernardi's review PTP inhibition
is only partially and indirectly achieved by available compounds
that act at the level of the PTP modulator cyclophilin D. A relevant
role in favoring PTP opening and exacerbating myocardial injury is
played by reactive oxygen species that, as reviewed by N.
Kaludercic, et al., are generated at various sites within mitochon-
dria. The control of these processes and especially of monoamine
oxidases appears to modulate not only I/R injury, but also the
transition from hypertrophy to failure.
Besides bioenergetic changes occurring at the mitochondrial
membranes, the adverse role played by high rates of fatty oxidation
in I/R hearts has been addressed by numerous studies spanning more
than four decades as reviewed by G. Lopaschuck et al. Notably, the
development of biochemical knowledge on expression and regulation
of enzymes and transporters involved in carbohydrate and lipid
oxidation has been instrumental in identifying potential targets for
achieving cardioprotection. Lipid metabolism is also the subject of J.G.
Duncan's review, which maintains the accent on mitochondrial
dysfunction but shifts the focus from the acute I/R damage to the
chronic setting of myocardial failure and especially of diabetic
cardiomyopathy. Finally, a more general review of the complex
relationships between mitochondrial alterations and contractile
failure is provided by R. Ventura-Clapier et al.
The issue is completed by two research articles on the control of
myocardial ionic homeostasis from O'Rourke's laboratory and on the
possible relevance of reactive oxygen species produced by mitochon-
dria before reperfusion as shown in the report from Schumackers'
laboratory
We hope that this issue will attract the interest not only of the vast
community of researchers in the cardiovascular area, but also of
biochemists and biophysicists that could fuel this ﬁeld with ﬁndings
aimed at elucidating novel mitochondrial mechanisms of myocardial
injury along with paving the way for novel therapies.
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tion of the relationships betweenmitochondrial dysfunction
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involvement of the permeability transition pore in myocar-
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used in studies in isolated cells and intact hearts. Moving
from the ischemia/reperfusion injury he is now focusing on
the role of mitochondria in heart failure by characterizing
processes involved in the mitochondrial formation of
reactive oxygen species as causative factors of perme-
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and investigate novel treatment strategies for protecting
the heart. More recently, he demonstrated the mitochon-
drial location of a highly expressed cellular protein(named connexin 43) being essential for cardioprotection. The latter is of utmost
importance since a number of human diseases (including genetic variations) are
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